MedTrace Logo

Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants

NCT05177029 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-07-12

No results posted yet for this study

Summary

The main goal of this study is to evaluate the effect of Lu AG06466 on the body and what the body does to Lu AG06466 after single and multiple doses to healthy Japanese and Caucasian participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Lu AG06466

Lu AG06466 will be administered per schedule specified in the arm.

DRUG

Placebo

Placebo matching to Lu AG06466 will be administered per schedule specified in the arm.

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

  • Email contact via H. Lundbeck A/S · H. Lundbeck A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-26
Primary Completion
2021-12-29
Completion
2021-12-29

Countries

  • Japan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05177029 on ClinicalTrials.gov